At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 41 enrolled
Drug / intervention
N6022 +1 moredrug
Likely dose
N6022 45 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single-Dose Escalation Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Effect of N6022 in Healthy Subjects
In Brief
A Phase 1 clinical trial evaluating N6022 and Placebo for Healthy. Completed, enrolled 41 participants across 1 site.
Detailed Summary
The purpose of this study is to evaluate the safety and tolerability of N6022 in healthy subjects.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesUnited States
Collaborators--
Timeline
Phase 1CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedJun 2010
Enrollment StartAug 2010
Primary CompletionJun 2011
TodayJul 2026
First PostedJun 22, 2010
Enrollment StartAug 1, 2010
Primary CompletionJun 1, 2011
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 16.0 years ago
Interventions
N6022drug
This is an injectible formulation which will be given at 5, 15 \& 45 mg over 1, 3 and 9 minutes respectively, in single ascending doses.
Placebodrug
This will be 0.9% normal saline given over 1, 3, or 9 minutes IV bolus.